trending Market Intelligence /marketintelligence/en/news-insights/trending/G_rI9NyVwE4SRBNSscxMcw2 content esgSubNav
In This List

Shandong Luoxin Pharma shareholders approve delisting of shares

Blog

Insight Weekly: M&A outlook; US community bank margins; green hydrogen players' EU expansion

Blog

Global M&A by the Numbers: Q2 2022

Blog

Insight Weekly: US bank M&A; low refinancing eases rates impact; Texas crypto mining booms

Blog

Infographic 2022 Top Tech Trends Shaping Corporations


Shandong Luoxin Pharma shareholders approve delisting of shares

Shandong Luoxin Pharmaceutical Group Stock Co. Ltd. shareholders approved the resolution for the proposed delisting of the company's H shares from The Stock Exchange of Hong Kong Ltd.

The H shares can be traded until June 5. Trading will be suspended June 6, and the shares will be delisted June 16.

Additionally, a voluntary conditional offer by Giant Star Global (HK) Ltd. and Ally Bridge Flagship LX (HK) Ltd. for all the issued H shares became unconditional on May 29. The offer will close June 26.